Teriflunomide real-world outcomes in the phase 4 Teri-PRO Study: Results from Europe, Canada, and Latin America

被引：0
|
作者：
Gold, R. [1 ]
Khatri, B. [2 ]
Edwards, K. R. [3 ]
Cavalier, S. [4 ]
Rufi, P. [5 ]
Thangavelu, K. [4 ]
Benamor, M. [5 ]
Coyle, P. K. [6 ]
机构：
[1] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[2] Wheaton Franciscan Healthcare, Reg MS Ctr, Ctr Neurol Disorders, Milwaukee, WI USA
[3] Multiple Sclerosis Ctr Northeastern New York, Latham, NY USA
[4] Sanofi Genzyme, Cambridge, MA USA
[5] Sanofi Genzyme, Chilly Mazarin, France
[6] SUNY Stony Brook, Stony Brook, NY 11794 USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2017年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1145
引用
收藏
页码：197 / 197
页数：1
相关论文
共 50 条
  • [1] Disability outcomes with teriflunomide: Results from the US and from Europe, Canada and Latin America in the real-world teri-PRO study
    Gold, R.
    Khatri, B.
    Edwards, K. R.
    Cavalier, S.
    Rufi, P.
    Thangavelu, K.
    Benamor, M.
    Coyle, P.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 495 - 495
  • [2] Teriflunomide real-world safety profile: results of the Phase 4 Teri-PRO Study
    Coyle, P. K.
    Khatri, B.
    Edwards, K. R.
    Meca Lallana, J.
    Cavalier, S.
    Rufi, P.
    Benamor, M.
    Brette, S.
    Gold, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 308 - 309
  • [3] Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study
    Coyle, Patricia K.
    Khatri, Bhupendra
    Edwards, Keith R.
    Meca-Lallana, Jose E.
    Cavalier, Steve
    Rufi, Pascal
    Benamor, Myriam
    Poole, Elizabeth M.
    Robinson, Miqun
    Gold, Ralf
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 : 157 - 164
  • [4] Real-world treatment satisfaction with teriflunomide: results from the European cohort of the phase 4 Teri-PRO study
    Vermersch, P.
    Meca Lallana, J.
    Maida, E.
    van Pesch, V.
    Kuusisto, H.
    Comi, G.
    Johansson, R.
    Rashid, W.
    Fakas, N.
    Rufi, P.
    Poole, E.
    Gold, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 868 - 869
  • [5] Treatment satisfaction with teriflunomide: preliminary results at week 4 for patients from Canada, Europe, and Latin America enrolled in the Teri-PRO phase-4 study
    Gold, R.
    Coyle, P. K.
    LaGanke, C.
    Khatri, B.
    Meca-Lallana, J.
    Cavalier, S.
    Brette, S.
    Baldinetti, F.
    Edwards, K. R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 826 - 826
  • [6] Impact of teriflunomide treatment on real-world quality of life in the Phase 4 Teri-PRO Study
    Gold, R.
    Khatri, B.
    Edwards, K. R.
    Cavalier, S.
    Rufi, P.
    Brette, S.
    Coyle, P. K.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 307 - 308
  • [7] Clinical and Safety Outcomes From Patients Treated With Teriflunomide in the Phase 4 Teri-PRO Study
    Gold, Ralf
    Khatri, Bhupendra
    Edwards, Keith R.
    Lallana, Jose Meca
    Cavalier, Steve
    Rufi, Pascal
    Benamor, Myriam
    Brette, Sandrine
    Chowdhury, Somankumar
    Coyle, Patricia K.
    [J]. NEUROLOGY, 2017, 88
  • [8] Lymphocyte Counts in Patients Treated With Teriflunomide: Observations From Phase 3 Clinical Trials and the Real-World Teri-PRO Study
    Coyle, Patricia
    Miller, Aaron
    Gold, Ralf
    Vermersch, Patrick
    Khatri, Bhupendra
    Benamor, Myriam
    Chavin, Jeffrey
    Thangavelu, Karthinathan
    Comi, Giancarlo
    [J]. NEUROLOGY, 2018, 90
  • [9] Improvements in patient-reported treatment satisfaction with teriflunomide: results from the Phase 4 Teri-PRO Study
    Coyle, P. K.
    Khatri, B.
    Edwards, K. R.
    Cavalier, S.
    Rufi, P.
    Brette, S.
    Gold, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 774 - 775
  • [10] Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study
    Coyle, Patricia K.
    Khatri, Bhupendra
    Edwards, Keith R.
    Meca-Lallana, Jose E.
    Cavalier, Steve
    Rufi, Pascal
    Benamor, Myriam
    Brette, Sandrine
    Robinson, Miqun
    Gold, Ralf
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 17 : 107 - 115
12345